COMPANY PROFILE // THE 014 REPORT
Sunshine Biopharma Inc.
SBFM (Nasdaq) · SBFMW (Nasdaq) · Formerly: Mountain West Business Solutions, Inc; mountain west business solutions,inc; mountain state business solutions,inc
Assembled from 3 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberNT 10-K filed on 2026-03-31: notice that a periodic report would be late (2 such notices in 24 months).
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-09-30 (last 24 months).
- InfoGLEIF: no direct parent reported; reporting exception reason NO_KNOWN_PERSON.
✓ SEC filings✓ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Sunshine Biopharma Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in CO, based in Fort Lauderdale, FL; listed as SBFM (Nasdaq), SBFMW (Nasdaq).[source] It reported revenue of $36.3 million for the fiscal year ended 2025-12-31.[source] It has filed 60 documents with the SEC in the last 12 months; the latest is a S-1, filed 2026-11-18.[source] Its largest institutional holders on 13F filings are JANE STREET GROUP, LLC, SBI Securities Co., Ltd., NATIONAL BANK OF CANADA /FI/ (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 4.01 filed; NT 10-K filed on 2026-03-31.[source]
- red0
- amber2
- info1
- JANE STREET GROUP, LLC$31K
- SBI Securities Co., Ltd.$340
- NATIONAL BANK OF CANADA /FI/$10
- OSAIC HOLDINGS, INC.$4
- Caitong International Asset Management Co., Ltd$2
- Farther Finance Advisors, LLC$2
- Strive Financial Group ,LLC$2
- TD Waterhouse Canada Inc.$2
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001402328 | source |
| LEI | 5299005Y64EHRQDQ2Q25 | source |
| EIN | 20-5566275 | source |
| Business address (SEC) | 333 LAS OLAS WAY, FORT LAUDERDALE, FL, 33301 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-16 · in 116 days · LEI next renewal (5299005Y64EHRQDQ2Q25)
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-18 filing Registration (S-1) · SEC EDGAR
- 2026-11-13 filing DEFA14A · SEC EDGAR
- 2026-11-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-12 filing Proxy statement · SEC EDGAR
- 2026-10-27 filing DEF 14C · SEC EDGAR
- 2026-10-14 filing PRE 14C · SEC EDGAR
- 2026-10-14 filing 8-K items 5.07 · SEC EDGAR
- 2026-10-09 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-10-09 filing 424B4 · SEC EDGAR
- 2026-10-07 filing EFFECT · SEC EDGAR
- 2026-10-02 filing Registration (S-1) · SEC EDGAR
- 2026-09-28 filing DEF 14C · SEC EDGAR
- 2026-09-24 filing DRS · SEC EDGAR
- 2026-09-16 filing PRE 14C · SEC EDGAR
- 2026-09-16 filing 8-K items 5.07 · SEC EDGAR
- 2026-09-11 filing 8-K items 8.01 · SEC EDGAR
- 2026-09-08 filing EFFECT · SEC EDGAR
- 2026-09-08 filing 424B3 · SEC EDGAR
- 2026-08-28 filing Registration (S-1) · SEC EDGAR
- 2026-08-28 officer change 8-K items 5.02 · SEC EDGAR
- 2026-08-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-03 filing 8-K items 8.01 · SEC EDGAR
- 2026-07-20 filing 424B5 · SEC EDGAR
- 2026-07-20 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-07-10 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-06-08 filing DEF 14C · SEC EDGAR
- 2026-05-29 filing PRE 14C · SEC EDGAR
- 2026-05-29 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-19 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-05-19 filing 424B4 · SEC EDGAR
170 earlier entries
- 2026-05-18 filing EFFECT
- 2026-05-18 filing CORRESP
- 2026-05-18 filing CORRESP
- 2026-05-14 filing CORRESP
- 2026-05-14 filing CORRESP
- 2026-05-13 filing Quarterly report (10-Q)
- 2026-05-12 filing Registration (S-1)
- 2026-05-04 filing UPLOAD
- 2026-04-28 filing DRSLTR
- 2026-04-28 filing DRS
- 2026-04-09 filing 8-K items 2.02,9.01
- 2026-04-03 filing Annual report (10-K)
- 2026-03-31 filing NT 10-K
- 2026-03-09 filing 8-K items 8.01,9.01
- 2026-03-02 filing DEF 14C
- 2026-02-20 filing 8-K items 5.07
- 2026-02-20 filing PRE 14C
- 2026-02-05 officer change 8-K items 5.02
- 2025-12-12 filing 8-K items 5.07
- 2025-11-13 filing Quarterly report (10-Q)
- 2025-10-23 filing DEFA14A
- 2025-10-23 filing Proxy statement
- 2025-09-30 filing 8-K items 4.01,9.01
- 2025-08-12 filing EFFECT
- 2025-08-12 filing Quarterly report (10-Q)
- 2025-08-12 filing 424B3
- 2025-08-12 filing RW
- 2025-08-11 filing UPLOAD
- 2025-08-11 filing CORRESP
- 2025-08-05 filing Registration (S-1)
- 2025-07-25 filing POS AM
- 2025-05-19 filing 8-K items 2.02,9.01
- 2025-05-15 filing Quarterly report (10-Q)
- 2025-04-03 filing 8-K items 1.01,8.01,9.01
- 2025-04-03 filing 424B5
- 2025-04-02 filing 8-K items 2.02,9.01
- 2025-04-01 filing Annual report (10-K)
- 2025-03-31 filing NT 10-K
- 2025-01-15 filing EFFECT
- 2025-01-15 officer change 8-K items 5.02,9.01
- 2025-01-13 filing CORRESP
- 2025-01-13 filing UPLOAD
- 2025-01-06 filing S-3
- 2024-12-10 filing 8-K items 5.07
- 2024-11-12 filing 424B4
- 2024-11-08 filing EFFECT
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-11-06 filing POS AM
- 2024-11-05 filing Quarterly report (10-Q)
- 2024-10-23 officer change 8-K items 5.02,9.01
- 2024-10-17 filing Proxy statement
- 2024-10-17 name change Name changed from Sunshine Biopharma, Inc
- 2024-09-10 filing 8-K items 8.01
- 2024-08-20 filing 10-Q/A
- 2024-08-19 filing 8-K items 2.02,9.01
- 2024-08-16 filing Quarterly report (10-Q)
- 2024-08-14 filing NT 10-Q
- 2024-08-12 filing 8-K items 5.03,9.01
- 2024-07-11 filing DEF 14C
- 2024-07-02 filing 8-K items 5.07
- 2024-07-01 filing PRE 14C
- 2024-07-01 filing 8-K items 8.01
- 2024-06-11 filing 8-K items 8.01
- 2024-06-07 filing 8-K items 3.01
- 2024-05-22 filing 8-K items 2.02,9.01
- 2024-05-20 filing Quarterly report (10-Q)
- 2024-05-15 filing NT 10-Q
- 2024-05-08 filing 8-K items 4.01
- 2024-05-06 filing 8-K items 4.01,9.01
- 2024-04-23 filing 8-K items 5.03,9.01
- 2024-04-01 filing 8-K items 2.02,9.01
- 2024-03-28 filing Annual report (10-K)
- 2024-03-15 filing DEF 14C
- 2024-03-06 filing 8-K items 1.01,3.02,5.07
- 2024-03-05 filing PRE 14C
- 2024-03-05 filing DEF 14C
- 2024-03-01 filing 8-K items 3.01
- 2024-02-21 filing PRE 14C
- 2024-02-16 filing 8-K items 5.07
- 2024-02-15 filing 8-K items 1.01,8.01,9.01
- 2024-02-14 filing 424B4
- 2024-02-12 filing EFFECT
- 2024-02-12 filing 8-K items 1.01,9.01
- 2024-02-09 filing CORRESP
- 2024-02-09 filing CORRESP
- 2024-02-09 filing S-1/A
- 2024-02-06 filing UPLOAD
- 2024-02-01 filing Registration (S-1)
- 2024-01-30 officer change 8-K items 5.02
- 2024-01-08 filing S-8
- 2023-12-07 filing 8-K items 5.07
- 2023-11-13 filing 8-K items 2.02,9.01
- 2023-11-13 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 1.02
- 2023-10-20 filing 8-K items 1.01,9.01
- 2023-10-19 filing DEFA14A
- 2023-10-18 filing Proxy statement
- 2023-10-13 filing 8-K items 5.07
- 2023-09-22 filing 8-K items 8.01
- 2023-09-05 filing Proxy statement
- 2023-08-29 filing UPLOAD
- 2023-08-25 filing PRE 14A
- 2023-08-11 filing 8-K items 2.02,9.01
- 2023-08-10 filing Quarterly report (10-Q)
- 2023-08-08 filing CORRESP
- 2023-07-25 filing UPLOAD
- 2023-06-05 filing EFFECT
- 2023-06-05 filing 424B3
- 2023-06-01 filing CORRESP
- 2023-06-01 filing UPLOAD
- 2023-05-25 filing S-3
- 2023-05-17 filing D
- 2023-05-16 filing 8-K items 1.01,3.02,8.01,9.01
- 2023-05-11 filing 8-K items 2.02,9.01
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-05-02 filing PRE 14A
- 2023-04-19 filing 8-K items 5.03,9.01
- 2023-04-04 filing Annual report (10-K)
- 2023-03-31 filing NT 10-K
- 2023-03-24 filing 8-K items 3.01
- 2023-02-28 filing 8-K items 1.01,7.01,9.01
- 2023-02-13 filing 8-K items 8.01
- 2023-02-10 filing 8-K items 1.01,7.01,9.01
- 2022-12-12 filing 8-K/A items 9.01
- 2022-12-09 filing 8-K items 3.01
- 2022-11-07 filing Quarterly report (10-Q)
- 2022-10-20 officer change 8-K items 1.01,2.01,3.02,5.02,7.01,9.01
- 2022-08-03 filing Quarterly report (10-Q)
- 2022-05-20 filing EFFECT
- 2022-05-20 filing 424B3
- 2022-05-18 filing CORRESP
- 2022-05-18 filing UPLOAD
- 2022-05-10 filing S-3
- 2022-05-06 filing Quarterly report (10-Q)
- 2022-04-29 filing D
- 2022-04-28 filing 8-K items 1.01,3.02,8.01,9.01
- 2022-04-08 filing EFFECT
- 2022-04-08 officer change 8-K items 5.02,9.01
- 2022-04-08 filing 424B3
- 2022-04-07 filing CORRESP
- 2022-04-07 filing UPLOAD
- 2022-03-30 filing S-3
- 2022-03-24 filing 8-K items 8.01,9.01
- 2022-03-21 filing Annual report (10-K)
- 2022-03-18 filing D
- 2022-03-15 filing 8-K items 1.01,3.02,8.01,9.01
- 2022-02-25 filing 8-K items 1.01,8.01,9.01
- 2022-02-17 filing 8-K items 1.01,8.01,9.01
- 2022-02-17 filing 424B4
- 2022-02-14 filing EFFECT
- 2022-02-14 filing S-1/A
- 2022-02-11 filing CERT
- 2022-02-10 filing 8-K items 5.03,9.01
- 2022-02-10 filing 8-A12B
- 2022-02-09 filing CORRESP
- 2022-02-09 filing CORRESP
- 2022-02-09 filing S-1/A
- 2022-02-08 filing 8-K items 7.01,9.01
- 2022-02-03 filing S-1/A
- 2022-01-24 filing S-1/A
- 2022-01-18 filing DEF 14C
- 2022-01-06 filing PRE 14C
- 2021-12-22 filing 8-K items 3.02,7.01,9.01
- 2021-11-09 filing Quarterly report (10-Q)
- 2021-11-03 officer change 8-K items 5.02,7.01,9.01
- 2021-10-06 filing DEF 14C
- 2021-09-21 filing PRE 14C
- 2021-09-16 filing UPLOAD
- 2021-09-09 filing Registration (S-1)
- 2021-08-09 filing Quarterly report (10-Q)
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-18 (within 7 days) S-1 filed (REGISTRATION STATEMENT)
- 2026-11-13 (within 30 days) DEFA14A filed (FORM DEFA14A)
- 2026-11-12 (within 30 days) 10-Q filed (FORM 10-Q FOR SEP 2026)
- 2026-11-12 (within 30 days) DEF 14A filed (DEFINITIVE PROXY STATEMENT)
- 2026-10-27 (within 30 days) DEF 14C filed (DEFINITIVE INFORMATION STATEMENT)
- 2026-10-14 (older) PRE 14C filed (PRELIMINARY INFORMATION STATEMENT)
- 2026-10-14 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-10-09 (older) 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:SBFM The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1402328 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | SBFM / Nasdaq, Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 5299005Y64EHRQDQ2Q25 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 5299005Y64EHRQDQ2Q25) | GLEIF |
| EIN | 205566275 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001402328 | SEC EDGAR / IRS |
| CUSIP | 867781809 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001402328 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $36,305,891 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-20 06:02 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$5,975,352 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 06:02 UTC | Report an error |
| Total assets (at 2025-12-31) | $30,079,167 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 06:02 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $23,038,460 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 06:02 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $9,123,308 | 2025-12-31 | 10-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | as filed | 2026-11-20 06:02 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 06:02 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 06:02 UTC | Report an error |
| State of incorporation | CO | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 06:02 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 06:02 UTC | Report an error |
| Business address | 333 LAS OLAS WAY, CU4 SUITE 433, FORT LAUDERDALE, FL, 33301 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 06:02 UTC | Report an error |
| Exchanges | Nasdaq, Nasdaq | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 06:02 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$5,331,073 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 06:02 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $174,491 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 06:02 UTC | Report an error |
| Form D total offering amount (D filed 2023-05-17) | $4,996,497 | 2023-05-17 | D | as filed | 2026-11-20 06:02 UTC | Report an error |
| Form D total amount sold (D filed 2023-05-17) | $4,996,497 | 2023-05-17 | D | as filed | 2026-11-20 06:02 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2023-05-17 | D | as filed | 2026-11-20 06:02 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2023-05-17 | D | as filed | 2026-11-20 06:02 UTC | Report an error |
| Form D date of first sale | 2023-05-12 | 2023-05-17 | D | as filed | 2026-11-20 06:02 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001683168-26-008624
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $9,442,325 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001683168-26-008624 | 2026-11-20 06:02 UTC | Report an error |
| Net income (loss) | -$1,223,940 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001683168-26-008624 | 2026-11-20 06:02 UTC | Report an error |
| Cash and cash equivalents | $14,618,614 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001683168-26-008624 | 2026-11-20 06:02 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-18 Filing S-1 filed (REGISTRATION STATEMENT)
- 2026-11-13 Filing DEFA14A filed (FORM DEFA14A)
- 2026-11-12 Filing 10-Q filed (FORM 10-Q FOR SEP 2026)
- 2026-11-12 Filing DEF 14A filed (DEFINITIVE PROXY STATEMENT)
- 2026-10-27 Filing DEF 14C filed (DEFINITIVE INFORMATION STATEMENT)
- 2026-10-14 Filing PRE 14C filed (PRELIMINARY INFORMATION STATEMENT)
- 2026-10-14 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-10-09 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-09 Filing 424B4 filed (PROSPECTUS)
- 2026-10-07 Filing EFFECT filed
- 2026-10-02 Filing S-1 filed (FORM S-1)
- 2026-09-28 Filing DEF 14C filed (DEFINITIVE INFORMATION STATEMENT)
- 2026-09-24 Filing DRS filed
- 2026-09-16 Filing PRE 14C filed (PRELIMINARY PROXY)
- 2026-09-16 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-09-11 Filing 8-K filed: Item 8.01 other event
- 2026-09-08 Filing EFFECT filed
- 2026-09-08 Filing 424B3 filed (FORM 424B3)
- 2026-08-28 Filing S-1 filed (FORM S-1)
- 2026-08-28 Filing 8-K filed: Item 5.02 officer or director change
- 2026-08-13 Filing 10-Q filed (FORM 10-Q FOR JUN 2026)
- 2026-08-03 Filing 8-K filed: Item 8.01 other event
- 2026-07-20 Filing 424B5 filed (PROSPECTUS SUPPLEMENT)
- 2026-07-20 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-07-10 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-10-14 8-K Item 5.07, Submission of Matters to a Vote of
Security Holders. On October 13, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent: · to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that closed on October 9, 2026 (the “Offering”). · to any adjustment to the exercise price or number of shares of common stock underlying the Series D Warrants issued in the Offering in the event… the 8-K · retrieved 2026-11-20 06:02 UTC - 2026-10-09 8-K Item 1.01, Entry into a Material Definitive
Agreement. On October 8, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering (the “Offering”) of (A) 10,509,082 common units (the “Common Units”), each consisting of (i) one share of the Company’s common stock, par value $0.001 per share (“Common Stock”), and (ii) two Series D warrants (the “Series D Warrants”), each exercisable for one share of Common Stock; and (B) 400,000 pre-funded units (the “Pre-Funded Units”), each consisting of (i) one pre-funded warrant (the “Pre-Funded Warrants”) to purchase one share of Common… the 8-K · retrieved 2026-11-20 06:02 UTC - 2026-10-09 8-K Item 8.01, Other Events
On October 8, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit 99.1 to this report. On October 9, 2026, the Company issued a press release announcing the closing of the Offering. A copy of the press release is filed as Exhibit 99.2 to this report. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Placement Agent Agreement 10.2 Form of Pre-Funded Warrant 10.3 Form of Series D Warrant 99.1 Press Release, dated October 8, 2026 99.2 Press Release dated October 9, 2026 104 Cover Page Interactive Data File (formatted in Inline XBRL). 3 the 8-K · retrieved 2026-11-20 06:02 UTC - 2026-09-16 8-K Item 5.07, Submission of Matters to a Vote of
Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s board of directors to effect a reverse split of the Company’s common in a ratio of up to 1-for-20, with the board of directors having the discretion as to whether or not the reverse split is to be effected, and with the exact ratio of any reverse split to be set at a whole number up to 1-for-20 as determined by the board in its discretion. The shareholder consent will be effective 20 days after the definitive information statement relating to such consent is… the 8-K · retrieved 2026-11-20 06:02 UTC - 2026-09-11 8-K Item 8.01, Other Events
As of the date of filing of this report, due to recent sales of Sunshine Biopharma Inc.’s (the “Company”) common stock under the Company’s previously disclosed at-the-market offering, the exercise price of the Company’s outstanding Series B Warrants has been reduced to $1.2046, subject to further adjustment as set forth under the Series B Warrants. 2 the 8-K · retrieved 2026-11-20 06:02 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | $31,445 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
| 2 | SBI Securities Co., Ltd. | $340 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
| 3 | NATIONAL BANK OF CANADA /FI/ | $10 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
| 4 | OSAIC HOLDINGS, INC. | $4 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
| 5 | Caitong International Asset Management Co., Ltd | $2 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
| 6 | Farther Finance Advisors, LLC | $2 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
| 7 | Strive Financial Group ,LLC | $2 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
| 8 | TD Waterhouse Canada Inc. | $2 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:02 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- Sunshine Biopharma, Inc. · LEI 5299005Y64EHRQDQ2Q25 · root
Exhibit 21 subsidiaries: not held yet.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1402328.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001402328. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.